These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20019088)

  • 1. Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy.
    Kodaira M; Takahashi S; Yamada S; Ueda K; Mishima Y; Takeuchi K; Yamamoto N; Ishikawa Y; Yokoyama M; Saotome T; Terui Y; Hatake K
    Ann Oncol; 2010 Jun; 21(6):1163-1167. PubMed ID: 20019088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carcinoma of unknown primary site: development in a single institution of a prognostic model based on clinical and serum variables.
    Ponce Lorenzo J; Segura Huerta A; Díaz Beveridge R; Giménez Ortiz A; Aparisi Aparisi F; Fleitas Kanonnikoff T; Richart Aznar P; de la Cueva Sapiña H; Montalar Salcedo J
    Clin Transl Oncol; 2007 Jul; 9(7):452-8. PubMed ID: 17652059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site.
    Seve P; Ray-Coquard I; Trillet-Lenoir V; Sawyer M; Hanson J; Broussolle C; Negrier S; Dumontet C; Mackey JR
    Cancer; 2006 Dec; 107(11):2698-705. PubMed ID: 17063500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of prognostic factors and the role of chemotherapy in unfavorable carcinoma of unknown primary site: a 10-year cohort study.
    Chen KW; Liu CJ; Lu HJ; Tzeng CH; Liu JH; Chiou TJ; Yen CC; Wang WS; Chao TC; Teng HW; Chen MH; Liu CY; Chang PM; Yang MH
    BMC Res Notes; 2012 Jan; 5():70. PubMed ID: 22280526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).
    Seifert H; Georgiou A; Alexander H; McLachlan J; Bodla S; Kaye S; Barton D; Nobbenhuis M; Gore M; Banerjee S
    Gynecol Oncol; 2015 Nov; 139(2):216-20. PubMed ID: 26318078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical characteristics of cancer of unknown primary (CUP)--a summary of 22 cases].
    Kato S; Yasuda K; Nishino Y; Ohori H; Takahashi M; Takahashi S; Yamaura G; Ohtsuka K; Kakudo Y; Chiba N; Shimodaira H; Sakayori M; Kato S; Suzuki T; Murakawa Y; Gamoh M; Shibata H; Yoshioka T; Ishioka C
    Gan To Kagaku Ryoho; 2007 Aug; 34(8):1227-31. PubMed ID: 17687203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study.
    Pentheroudakis G; Briasoulis E; Kalofonos HP; Fountzilas G; Economopoulos T; Samelis G; Koutras A; Karina M; Xiros N; Samantas E; Bamias A; Pavlidis N;
    Acta Oncol; 2008; 47(6):1148-55. PubMed ID: 18607872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.
    Hainsworth JD; Erland JB; Kalman LA; Schreeder MT; Greco FA
    J Clin Oncol; 1997 Jun; 15(6):2385-93. PubMed ID: 9196154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site.
    van der Gaast A; Verweij J; Planting AS; Hop WC; Stoter G
    J Clin Oncol; 1995 Jul; 13(7):1720-5. PubMed ID: 7541451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study.
    Seve P; Sawyer M; Hanson J; Broussolle C; Dumontet C; Mackey JR
    Cancer; 2006 May; 106(9):2058-66. PubMed ID: 16583433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin.
    Greco FA; Erland JB; Morrissey LH; Burris HA; Hermann RC; Steis R; Thompson D; Gray J; Hainsworth JD
    Ann Oncol; 2000 Feb; 11(2):211-5. PubMed ID: 10761758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature.
    Lazaridis G; Pentheroudakis G; Fountzilas G; Pavlidis N
    Cancer Treat Rev; 2008 Dec; 34(8):693-700. PubMed ID: 18584969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic and predictive factors of patients with cancer of unknown origin treated with a paclitaxel-based chemotherapy].
    Muñoz A; Fuente N; Barceló R; Rubio I; Ferreiro J; López Vivanco G
    Med Clin (Barc); 2004 Feb; 122(6):216-8. PubMed ID: 15012889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New prognostic index to predict survival in patients with cancer of unknown primary site with unfavourable prognosis.
    Trivanović D; Petkovic M; Stimac D
    Clin Oncol (R Coll Radiol); 2009 Feb; 21(1):43-8. PubMed ID: 18976894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network.
    Shaw PH; Adams R; Jordan C; Crosby TD
    Clin Oncol (R Coll Radiol); 2007 Feb; 19(1):87-95. PubMed ID: 17305260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line chemotherapy in patients with primary unknown cancer.
    Ono M; Ando M; Yonemori K; Yamamoto H; Hirata T; Shimizu C; Tamura K; Katsumata N; Fujiwara Y
    J Cancer Res Clin Oncol; 2011 Aug; 137(8):1185-91. PubMed ID: 21559815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-marker analysis and verification of prognostic models in patients with cancer of unknown primary, receiving platinum-based combination chemotherapy.
    Yonemori K; Ando M; Shibata T; Katsumata N; Matsumoto K; Yamanaka Y; Kouno T; Shimizu C; Fujiwara Y
    J Cancer Res Clin Oncol; 2006 Oct; 132(10):635-42. PubMed ID: 16791594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
    Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
    Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial.
    Hainsworth JD; Daugaard G; Lesimple T; Hübner G; Greco FA; Stahl MJ; Büschenfelde CM; Allouache D; Penel N; Knoblauch P; Fizazi KS
    Cancer; 2015 May; 121(10):1654-61. PubMed ID: 25611313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy.
    Pond GR; Di Lorenzo G; Necchi A; Eigl BJ; Kolinsky MP; Chacko RT; Dorff TB; Harshman LC; Milowsky MI; Lee RJ; Galsky MD; Federico P; Bolger G; DeShazo M; Mehta A; Goyal J; Sonpavde G
    Urol Oncol; 2014 May; 32(4):501-8. PubMed ID: 24332646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.